news
Major immunotherapy trial sees survival benefit in solid tumours
A key barrier in delivering this type of therapy to patients was overcome in the first-of-a-kind T cell therapy trial, data shows.
List view / Grid view
Biologics
news
Single-use bioreactor market to witness favourable expansion to 2030
Advancement in technology like automation is boosting the adoption of single-use technology rocking bioreactors in the bioprocess market, research says.
news
First-of-a-kind EU approval granted for eosinophilic esophagitis medicine
With its novel approach for addressing a fundamental cause of eosinophilic esophagitis, approval of the biologic marks a potential new standard of care for paediatric patients.
whitepaper
Whitepaper: Risk-Based Approach to Development – Injectable Combination Product
Drug-device combination products offer advantages for patients but are complex and challenging to develop. Establish a holistic approach to DDCP development and assess and manage risk throughout the process.
webinar
When Innovative Formulations Cloud Sterility Testing
30 October 2024 | By Charles River
Webinar presented by Miriam Guest, Senior Principal Scientific Advisor at Charles River, to explore how ATP-bioluminescence outperforms traditional sterility testing in complex matrices.
news
AbbVie agrees $1.4 billion Alzheimer’s acquisition
The deal will help AbbVie to strengthen its neuroscience pipeline, including supporting development of next-generation therapies for delivery into the central nervous system.
webinar
The path to optimisation in pharmaceutical microbiology
29 October 2024 | By European Pharmaceutical Review
During this virtual panel, industry experts will delve into the latest advances and biggest challenges in pharmaceutical microbiology today.
news
ACG 2024: J&J data reveals new Crohn’s treatment option
More patients given subcutaneous induction and maintenance treatment with Johnson & Johnson’s biologic obtained clinical remission at 48 weeks, compared to placebo, Phase III data showed.
news
Trial highlights potential next-gen biologic for lung cancer
Preliminary results from an ongoing trial of a novel monoclonal antibody have confirmed favourable efficacy and safety in recurrent extensive-stage small cell lung cancer (SCLC).
whitepaper
Delivering market success for concept to patient
24 October 2024 | By
Whitepaper - Delivering Market Success for Pharma Partners from Concept to Patient
article
Developing donanemab – balancing cost versus benefit
This article summarises recent regulatory developments surrounding the Alzheimer’s treatment donanemab and considers the future therapeutic market for this disease.
news
Eli Lilly secures MHRA authorisation for Alzheimer’s treatment
Authorisation in Great Britain means eligible Alzheimer's patients can access the treatment, which is part of a new class of amyloid targeting therapies.
news
World-first medicine manufacturing regulatory framework to be implemented
The new regulation could become lawful in the UK next year, according to the Medicines and Healthcare products Regulatory Agency (MHRA).
webinar
Turning quality management into quality leadership
9 October 2024 | By MasterControl
This webinar discusses the power of a comprehensive QMS to ensure efficiency, compliance, and product quality.
whitepaper
A data-driven approach to Container Closure Integrity
Selecting container closure components with confidence:A data-driven approach to Container Closure Integrity.
